Biomarkers in oncology trials: Mankoff and colleagues offer an introductory focus on cancer biomarkers and their applications in molecular imaging studies in clinical trials, with a focus on individualizing therapy.
Page 525
State of clinical PET/MR: Mansi and Ciarmiello look at the challenges and promise associated with integration of PET/MR into routine use, including instrumentation, new indications, and the need for specific expertise in interpretation.
Page 529
PET/CT with sodium 18F-fluoride: Segall summarizes current practices in bone imaging with NaF in prostate cancer, including relevant trials, alternative approaches, and regulatory status.
Page 531
131I-huA33 and capecitabine therapy: Herbertson and colleagues use a combined chemoradiation regimen, including a humanized antibody that targets the A33 antigen, to treat patients with metastatic colon cancer.
Page 534
PET and MR in brain tumors: Filss and colleagues compare the accuracy of 18F-FET PET and perfusion-weighted MR imaging, including maps of regional cerebral blood volume, in patients with gliomas and meningiomas.
Page 540
Diffusivity and amino acid PET: Rahm and colleagues use diffusion-weighted MR and 18F-FET PET imaging to assess focal changes in diffusion and amino acid uptake in patients with nonenhancing low-grade gliomas.
Page 546
Relative contributions of PET and MR: Kuhn and colleagues report on a study designed to elucidate which portions of 18F-FDG PET/MR data enhance the sensitivity and specificity of the hybrid examination in patients with head and neck cancer.
Page 551
Mediastinal N-staging in lung cancer: Flechsig and colleagues determine whether volumetric CT histogram analysis can improve the characterization of lymph nodes in 18F-FDG PET/CT staging of patients with lung cancer.
Page 559
PET in pulmonary amyloidosis: Baqir and colleagues present imaging findings in a group of patients with primary amyloidosis and characterize 18F-FDG PET results that may suggest the presence of neoplasms.
Page 565
PET and prognosis in Hodgkin lymphoma: Rossi and colleagues compare the utility of visual (5-point scale) and semiquantitative (change in uptake) methods for assessment of interim PET imaging in patients with first diagnoses of Hodgkin lymphoma.
Page 569
NOPR NaF PET in prostate cancer: Hillner and colleagues review initial results from National Oncologic PET Registry data on the use of 18F-sodium fluoride PET in identifying osseous metastases in men with known prostate cancer.
Page 574
PET in colon cancer liver metastasis: Lee and colleagues assess the prognostic ability of preoperative 18F-FDG PET/CT in patients with synchronous colorectal cancer liver metastases after curative-intent colorectal and liver surgery.
Page 582
18F-FDGal lumped constant in cirrhosis: Mikkelsen and colleagues test the hypothesis that the calculated lumped constant for 18F-FD-galactose PET imaging in patients with parenchymal liver disease differs significantly from that in healthy individuals.
Page 590
Novel phosphodiesterase 10A radioligands: Plisson and colleagues describe progressive studies with 11C-labeled PET tracers in pig and primate brain and evaluation of the most promising tracer in humans.
Page 595
Lesion uptake in TOF PET: Daube-Witherspoon and colleagues assess the impact of time-of-flight information on the accuracy and precision of quantitative measurements of activity uptake on PET in small lesions in clinical studies.
Page 602
Radionuclides in nephrology: Taylor provides the first of 2 educational overviews, with a focus on radiopharmaceuticals, quality control, and quantitative indices in renal scintigraphy.
Page 608
18F-FBPA-Fr pharmacokinetics: Yang and colleagues investigate the distribution and uptake of this tracer after ultrasound-induced blood–brain barrier disruption for potential enhancement of boron delivery in neutron capture therapy.
Page 616
hCtr1 in prostate cancer: Cai and colleagues research the mechanisms of cellular uptake on 64CuCl2 PET imaging and explore the functional role of human copper transporter 1 in prostate cancer cell proliferation and tumor growth.
Page 622
Nanoparticle imaging of CCR5: Luehmann and colleagues describe the development of a targeted nanoparticle for sensitive and specific PET/CT imaging of the chemokine receptor 5 and initial studies in a mouse model of vascular injury.
Page 629
PET neuropeptide Y2 imaging: Winterdahl and colleagues detail the development of a novel positron-emitting radioligand based on an NPY2 receptor antagonist and describe initial PET brain imaging studies in pigs.
Page 635
5-HT7 receptor radioligands: Hansen and colleagues present the radiosynthesis and preclinical in vivo evaluation of 2 novel 11C-labeled tracers for investigation of 5-HT7R binding in the living brain.
Page 640
Effects of haloperidol on DAT: Booij and colleagues report on a study in rats to determine whether the extent of change in synaptic dopamine resulting from acute haloperidol administration is detectable with 123I-FP-CIT SPECT.
Page 647
Targeted anti-HER2 Nanobody: Pruszynski and colleagues evaluate the tumor-targeting potential of an anti–human epidermal growth factor receptor type 2 Nanobody conjugate with promise for PET and SPECT imaging and for targeted radiotherapy.
Page 650
Oxidative stress PET imaging: Webster and colleagues report on the synthesis and in vivo validation of 18F-5-fluoro-aminosuberic acid, a PET tracer with potential for functional imaging of cellular response to oxidative stress in tumors.
Page 657
89Zr-labeled anticalin and oncogene targeting: Terwisscha van Scheltinga and colleagues describe engineering of anticalin PRS-110 to target the oncogene MET, visualization of MET expression, and biodistribution in human tumor–bearing mice.
Page 665
18F-ASEM PET imaging of α7-nAChR: Horti and colleagues evaluate the potential of a novel 18F-labeled tracer for PET quantification of α7-nicotinic cholinergic receptor in the living brain.
Page 672
HDACI-mediated cancer targeting: Hsieh and colleagues report on a novel reporter gene system to evaluate the anticancer effect of histone deacetylase inhibitors on cancer cells, with relevance to multiple molecular imaging modalities.
Page 678
Imaging metastasis and heterogeneity: Fruhwirth and colleagues detail the development of a new whole-body nano-SPECT/CT longitudinal model for in vivo imaging of spontaneous cancer cell metastases and heterogeneous tumor responses to drug treatment.
Page 686
- © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.